



Affiliated to International Society of Addiction Medicine

13th European Congress

Heroin Addiction & Related Clinical Problems

European Opiate Addiction Treatment Association - EUROPAD



25-27 May 2018

Jagiellonian University

KRAKOW POLAND-EU



Under the co-patronage of
Santa Chiara University Hospital, Pisa, Italy, EU





EUROPEAN OPIATE ADDICTION TREATMENT ASSOCIATION

EUROPAD formerly EUMA was founded in Geneva (Switzerland) on September 26, 1994. It shall remain independent of political parties and of any government.

The vision

EUROPAD exists to improve the lives of opiate misusers and their families and to reduce the impact of illicit drug use on society as a whole. The Association works to develop opiate addiction treatment in Europe but also aims to make a major contribution to the knowledge of, and attitudes to, addiction treatment worldwide

Scientific Committee of the 13th Congress

Coordinators

Icro Maremmani (Pisa, Italy)
Edward Jacek Gorzelanczyk (Bydgoszcz, Poland)
Marc Reisinger (Brussels, Belgium)
Andrej Kastelic (Ljubljana, Slovenia)

Local Scientific Committee

Tadeusz Marek (Krakow, Poland)
Irena Roterman-Konieczna (Krakow, Poland)

International Scientific Committee

Adrian-Octavian Abagiu (Bucarest, Romania)	Genci Mucullari (Tirana, Albania)
Hannu Alho (Helsinki, Finland)	Lubomir Okruhlica (Bratislava, Slovak Republic)
Marc Auriacombe (Bordeaux, France)	Mark Parrino (New York, New York, USA)
Michael Farrel (Sydney, New South Wales, Australia)	Luis Patricio (Lisbon, Portugal)
Loretta Finnegan (Satellite Beach, Florida, USA)	Einal Peles (Tel Aviv, Israel)
Gabriele Fischer (Vienna, Austria)	Giulio Perugi (Pisa, Italy)
Gilberto Gerra (UNODC)	Jens Reimer (Hamburg, Germany)
Milazim Gjocaj (Pristina, Kosovo)	Marta Torrens (Barcelona, Spain)
Liljana Ignjatova (Skopje, Macedonia)	Didier Touzeau (Bagneux France)
Ante Ivancic (Porec, Croatia)	Ambros Uchtenhagen (Zurich, Switzerland)
Minja Jovanovic (Kragujevac, Serbia)	Albrecht Ulmer (Stuttgart, Germany)
Alexander Kantchelov (Sofia, Bulgaria)	Peter Vossenbergh (Deventer, The Netherlands)
Mercedes Lovrecic (Ljubljana, Slovenia)	Helge Waal (Oslo, Norway)
Angelo G. I. Maremmani (Viareggio, Italy)	Stephan Walcher (Munich, Germany)
Garret McGovern (Dublin, Ireland)	George Woody (Philadelphia, Pennsylvania, USA)

Under the Patronage of

World Federation for the Treatment of Opioid Dependence, New York, NY, USA
NGO with Special Consultative Status with United Nations Economic and Social Council (ECOSOC)

Jagiellonian University, Krakow, Poland

Santa Chiara University Hospital, Pisa, Italy

Promoted by

European Opiate Addiction Treatment Association

Association for the Application of Neuroscientific Knowledge to Social Aims, Lucca, Italy

Congress Presidents

EDWARD JACEK GORZELANCZYK (Bydgoszcz, Poland)

ICRO MAREMMANI (Pisa, Italy)

Local Scientific Committee

Tadeusz Marek (Krakow, Poland)

Irena Roterman-Konieczna (Krakow, Poland)

Venue

Jagiellonian University
Gołębia 24, 31-007 Kraków, Poland

Phone: +48 12 422 10 33

<http://www.en.uj.edu.pl/>

Organizing Committee

Ti.Gi. Congress, Via Udine, 12 - 58100 GROSSETO, Italy

Phone +39 0564412038 - Fax +39 0564412485

E-mail: giusi@tigicongress.com

AU-CNS, Via XX Settembre, 83 - 55045 PIETRASANTA, LU, Italy

Phone +39 0584790073 - Fax +39 058472081

E-mail: info@aucns.org

Room and time ABSTRACT
No

PROGRAM

FRIDAY MAY 25, 2018

SELECTED ORAL PRESENTATIONS

Room A	Europad Selected Presentations <i>Chair: Angelo G.I. Maremmani (Viareggio, Italy, EU)</i>	
12:00	SOP-01	ADRIAN O. ABAGIU (Bucarest, Romania, EU) - 5 years of methadone maintenance treatment in arena OMT center-Bucharest
12:20	SOP-02	OLAV DALGARD (Oslo, Norway) - Sofosbuvir-based direct-acting antiviral therapies for hcv in people receiving opioid substitution therapy: An analysis of phase 3 studies
12:40	SOP-03	OLAV DALGARD (Oslo, Norway) - Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injecting drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial
13:00	SOP-04	ALICE DESCHENAU (Villejuif, France, EU) - Addict Assist: a study about acceptability of a questionnaire to assess substance use troubles in a French psychiatric hospital
13:20	SOP-05	FELICIA HEIDEBRECHT (London, UK) - Predictors of poor health and heroin use in methadone-treated injecting heroin users: The importance of methadone dosage and crack cocaine use
13:40	SOP-06	BODIL MONWELL (Jönköping, Sweden, EU) - Opiates versus other opioids - are these relevant diagnostics?
14:00	SOP-07	EINAT PELES (Tel Aviv, Israel) - Cannabis use is associated with worse methadone maintenance treatment outcome but not among schizophrenia and other psychotic patients
14:20	SOP-08	OMRI SINAI (Tel Aviv, Israel) - Induced delusional disorder among opiate users: A case report
14:40	SOP-09	JAMIE WILLIAMS (Providence, Rhode Island, USA) - Clinical and psychological interventions in heroin addiction. Spiritual approach for the treatment of opioid addiction

SPECIAL EVENTS

Plenary Room	Lecture <i>Chair: Icro Maremmani (Pisa, Italy, EU)</i>	
15:30	SE1-1	AUTHOR (City, Country) - Title

Room and time ABSTRACT
No

FRIDAY MAY 25, 2018

Plenary Room

PLENARY SESSION

Chair: *Icro Maremmanni (Pisa, Italy, EU)*
Edward J. Gorzelanczyk (Bydgoszcz, Poland, EU)

17:15	PS1	ICRO MAREMMANI (Pisa, Italy, EU) & EDWARD J. GORZELANCZYK (Bydgoszcz, Poland, EU) - Conference Opening
17:30	PS2	MARK PARRINO (New York, NY, USA) - Title tbc
18:00	PS3	MAURICE DEMATTEIS (Grenoble, France, EU) - Agonist opioid therapeutic strategies: Which treatment for which patients?
19:00	PS4	LORETTA FINNEGAN (Avalon, NJ, USA) - "You've come a long way baby!" Neonatal Abstinence Syndrome and progress over 5 decades
20:00		BREAK
20:30		WELCOME COCKTAIL AND EUROPAD CHIMERA AWARD 2018
	TO BE AWARDED:	MAURICE DEMATTEIS (Grenoble, France, EU) MATTEO PACINI (Pisa, Italy, EU) GABRIELLE WELLE-STRAND (Oslo, Norway)
	CAREER AWARD:	MARK PARRINO (New York, NY, USA)

FORMER RECIPIENTS:

Marc Auriacombe (France) - 2002
Olof Blix (Sweden) - 2000
Miguel Casas (Spain) - 2012
Thomas Clausen (Norway) - 2014
Pascal Courty (France) - 2012
Jean-Jacques Deglon (Switzerland) - 2004
Sergey Dvoryak (Ukraine) - 2010
Gabriele Fischer (Austria) - 2008
Gilberto Gerra (Italy) - 2006
Ante Ivancic (Croatia) - 2006
Alexander Kantchelov (Bulgaria) - 2004
Andrej Kastelic (Slovenia) - 2008
Mercedes Lovrecic (Slovenia) - 2002

Vladimir Mendelevich (Russia) - 2014
Lubomir Okruhlica (Slovak Republic) - 2002
Pier Paolo Pani (Italy) - 2004
Luis Patricio (Portugal) - 2010
Einat Peles (Israel) - 2016
Slavko Sakoman (Croatia) - 2010
Lorenzo Somaini (Italy) - 2014
Marta Torrens (Spain) - 2006
Didier Touzeau (France) - 2008
Ambros Uchtenhagen (Switzerland) - 2016
Peter Vossenbergh (The Netherlands) - 2016
Helge Waal (Norway) - 2012

FORMER CAREER AWARD RECIPIENTS:

Jean-Pierre Daulouede (France) - 2016
Loretta Finnegan (USA) - 2010
Mary Jeanne Kreek (USA) - 2014
Joyce Lowinson (USA) - 2007

Icro Maremmanni (Italy) - 2004
Robert Newman (USA) - 2012
Marc Reisinger (Belgium) - 2004
Alessandro Tagliamonte (Italy) - 2004

Room and time	ABSTRACT No
SATURDAY MAY 26, 2018	
SPECIAL EVENT	
Plenary Room	Lecture <i>Chair: Author (City, Country)</i>
8:30	SE1-1 AUTHOR (City, Country) - Title
PLENARY SESSION <i>Chair: Marc Reisinger (Brussels, Belgium, EU) Edward J. Gorzelanczyk (Bydgoszcz, Poland, EU)</i>	
9:30	PS5 AUTHOR (City, Country) - Title
10:30	COFFEE BREAK
11:00	PARALLEL SYMPOSIA
Plenary Room	1 - Prisoners with substance use disorder and other co-morbidities – medical and human rights considerations <i>Chair: Gabriele Fischer (Vienna, Austria, EU) - Marta Torrens (Barcelona, Spain, EU)</i>
11:00	S01-1 DAGMAR HEDRICH (Lissabon, Portugal, EU) - Opioid maintenance in European prisons: Is the treatment gap closing ? – From an European Perspective
11:30	S01-2 PETER KASTNER (Vienna, Austria, EU) - OPCAT Mandate in Europe highlighting results from Austria in improving accessibility to medical care for prisoners under the legal mandate (2012-2017)
12:00	S01-3 MARI AMOS (Tallin, Estonia, EU) - Preventive Human Rights Protection for prisoners in health issues – an international perspective
12:30	S01-4 ROCIO MARTIN-SANTOS (Barcelona, Spain, EU) - Cost effectiveness and management of hepatitis C treatment in patients with substance use disorder
Room A	2 - Expanding access to buprenorphine treatment <i>Chair: Christopher Welsh (Baltimore, MD, USA)</i>
11:00	S02-1 YNGVILD OLSEN (Baltimore, MD, USA) - Overview of the problem and structural obstacles to implementing change
11:30	S02-2 ERIC WEINTRAUB (Baltimore, MD, USA) - TELE-BUP: prescribing buprenorphine to patients in underserved areas using tele-medicine
12:00	S02-3 CHRISTOPHER WELSH (Baltimore, MD, USA) - Initiating buprenorphine from the emergency department or hospital: capitalizing on the window of opportunity
12:30	S02-4 AARON GREENBLATT (Baltimore, MD, USA) - Telephone consultation to primary care providers: trying to increase prescriber comfort
Room B	3 - Opioid addiction mechanisms <i>Chair: Wojciech Solecki (Krakow, Poland, EU)</i>
11:00	S03-1 WOJCIECH SOLECKI (Krakow, Poland, EU) - Behavioral and molecular endophenotypes of opioid addiction
11:30	S03-2 MICHAŁ KIEŁBIŃSKI (Krakow, Poland, EU) - Ventral tegmental area regulation of cocaine and oxycodone craving
12:00	S03-3 ADAM HAMED (Warsaw, Poland, EU) - Serotonin and glutamate co-transmission in reward anticipation measured by 50-khz ultrasonic vocalization in morphine conditioned context
12:30	S03-4 KAROLINA KARWOWSKA (Krakow, Poland, EU) - Motivational and physiological symptoms of morphine physical dependence - role of adrenergic and corticoid receptor mechanisms

Room and time	ABSTRACT No
13:15	CONFERENCE LUNCH
14:30	PARALLEL SYMPOSIA - SATURDAY MAY 26, 2018
Plenary Room	4 - Continuity of treatment in Israel <i>Chair: Suzan Ben Ezra (Jerusalem, Israel)</i>
14:30	S04-1 ARTURO G. LERNER (Natania, Israel) - Ayahuasca in the treatment and harm reduction of substance use disorder- Mechanism of action and clinical aspects
15:00	S04-2 SHIRLEY HERTZ-KEISAR (Ness Ziona, Israel) - The new Dual Disorders division – System in progress
15:30	S04-3 ILAN TAL, (Tel Aviv, Israel) - Multi-disciplinary model for prescription opioids misuse in private setting
16:00	S04-4 MICHAEL AMNON (Haifa, Israel) - The connection between resilience and craving among inpatient programs
Room A	5 - Novel psychoactive substances: psychiatric consequences and related behavioural addictions <i>Chair: Rok Tavcar (Ljubljana, Slovenia, EU)</i>
14:30	S05-1 ROK TAVCAR (Ljubljana, Slovenia, EU) - Novel psychoactive substances: what every clinician needs to know about
15:00	S05-2 MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Novel synthetic cannabinoids: lessons learned
15:30	S05-3 BARBARA LOVRECIC (Ljubljana, Slovenia, EU) - Novel synthetic cathinones: lessons learned
16:00	S05-4 MOJCA ZVEZDANA DERNOVSEK (Ljubljana, Slovenia, EU) - Assessing, treatment and clinical management of psychiatric consequences of novel psychoactive substances use and related behavioural addictions
Room B	6 - Addictive Disorders: Pre-existing factors and specific psychopathology <i>Chair: Icro Maremmanni (Pisa, Italy, EU)</i>
14:30	S06-1 IACOPO BELCARI (Pisa, Italy, EU) - Are personality disorders pre-existing factors of addictive behaviour?
15:00	S06-2 LUCA ROVAI (Pisa, Italy, EU) - Are affective temperaments pre-existing factors of addictive behaviour?
15:30	S06-3 ANGELO G.I. MAREMMANI (Pisa, Italy, EU) - Towards a specific psychopathology of Substance Use Disorders
16:00	S06-4 ICRO MAREMMANI (Pisa, Italy, EU) - Should emotional responses to life events be included in the specific psychopathology of Substance Use Disorders?
16:30	COFFEE BREAK

Room and time	ABSTRACT No	
17:00		PARALLEL SYMPOSIA, SATURDAY MAY 26, 2018
Plenary Room	ABSTRACT No	7 - Supporting recovery and normalizing life of people in OAT programmes <i>Chair: Andrej Kastelic (Ljubljana, Slovenia, EU) - Liljana Ignatova (Skopje, Macedonia)</i>
17:00	S07-1	LILJANA IGNJATOVA (Skopje, Macedonia) - Stigma and secrecy coping in individuals in treatment for substance dependence in Macedonia and Slovenia
17:30	S07-2	NUSA SEGEC (Ljubljana, Slovenia, EU) - Reducing discrimination - treating difficult to reach populations with mental health and substance use disorders
18:00	S07-3	MIRA DELIC (Ljubljana, Slovenia, EU) - Employability of patients with opioid addiction
18:30	S07-4	ANDREJ KASTELIC (Ljubljana, Slovenia, EU) - Ability for driving of people in AOT programmes
Room A		8 - Hot topics in Heroin Use Disorder patients <i>Chair: Thomas Clausen (Oslo, Norway)</i>
17:00	S08-1	EINAT PELES (Tel Aviv, Israel) - Can a measure of heart rate variability serve as a marker for stress among patients in methadone maintenance treatment (MMT)?
17:30	S08-2	MARC REISINGER (Brussels, Belgium, EU) - Opiate addiction treatment and free movement in the Schengen Area : A complaint against Norway
18:00	S08-3	GABRIELLE K. WELLE-STRAND (City, Country) - Title tbc
18:30	S08-4	THOMAS CLAUSEN (Oslo, Norway) - The use of non-prescribed benzodiazepines and/or amphetamines predict treatment instability in opioid maintenance treatment
Room B		9 - Harm reduction in Israel policy, programs and research <i>Chair: Hgal Brosh (Jerusalem, Israel)</i>
17:00	S09-1	SUZAN BEN EZRA (Jerusalem, Israel) - "A thousand-mile journey begins with one step" - a "first step" for drug and alcohol addicts
17:30	S09-2	HAIM MELL (Afula, Israel) - HIV outbreak related to injection of new psychoactive substances in Tel Aviv, Israel
18:00	S09-3	HAGIT BONNY-NOACH (Ariel, Israel) - Injecting drug use, sex work and differential harm reduction approaches for women: ethnographic study in Israel's largest open drug scene
18:30	S09-4	PAOLA ROSCA (Jerusalem, Israel) - Infectious diseases among omt patients in Israel - results of a historical cohort study and the new treatment policy
Break-out Room	ABSTRACT No	9B - Multicenter study on opioid misuse before entering Agonist Opioid Treatment in Europe (in collaboration with RADAR system) <i>Chair: Karin McBride (Denver, CO, USA)</i>
19:00	S07-5	Group meeting (by invitation only)
20:45		SPEAKERS' DINNER* Restaurant tbc - Krakow, Poland, EU
		* Tickets are available for all delegates

Room and time	ABSTRACT No	
SUNDAY MAY 27, 2018		
SPECIAL EVENT		
Plenary Room		Lecture <i>Chair: Author (City, Country)</i>
8:00	SE1-1	AUTHOR (City, Country) - Title
Plenary Room		PLENARY SESSION <i>Chair: Andrej Kastelic (Ljubljana, Slovenia)</i> <i>Edward J. Gorzelanczyk (Bydgoszcz, Poland, EU)</i>
9:00	PS6	AUTHOR (City, Country) - Title
10:00		PARALLEL SYMPOSIA
Plenary Room		10 - Psychological therapies and interventions in the treatment of opiate use disorder <i>Chair: Alexander Kantchev (Sofia, Bulgaria, EU)</i>
10:00	S10-1	PAUL DELANEY (Dublin, Ireland, EU) - Why a willingness to change is often not sufficient – utilizing motivational interviewing to develop self-efficacy and confidence to change
10:30	S10-2	ALBRECHT ULMER (Stuttgart, Germany, EU) - How to touch the souls of our addicted patients better
11:00	S10-3	ALEXANDER BELCHEV (London, UK) - Integrative therapeutic model of recovery network Turning Point South London, UK
11:30	S10-4	JOÃO G. PEREIRA (Lisbon, Portugal, EU) - Attachment theory and open dialogue in addictions: How can mentalizing help?
Room A		11 - Hot topics in Heroin Use Disorder patients <i>Chair: Matteo Pacini (Pisa, Italy, EU)</i>
10:00	S11-1	FRANCINA FONSECA (Barcelona, Spain, EU) - Benzodiazepines use “to get high” in patients admitted for addiction treatment in Spain
10:30	S11-2	MARTIN HARALDSEN (Larvik, Norway) - Agonist opioid treatment (AOT) with buprenorphine (BPN) and often benzodiazepine (BZD) in the GP-setting: Enabling a normalized life
11:00	S11-3	ALEXANDER KANTCHELOV (Sofia, Bulgaria, EU) - The reverse tolerance effect in methadone treated patients
11:30	S11-4	MATTEO PACINI (Pisa, Italy, EU) - Benzodiazepine Use Disorder in patients with and without Opioid Use Disorder
Room B		12 - A new way to think about Dual Disorders: Opioid System and Mental Disorders in collaboration with World Association on Dual Disorder (WADD) <i>Chair: Miguel Casas (Barcelona, Spain, EU)</i>
10:00	S12-1	NESTOR SZERMAN (Madrid, Spain, EU) - Opioid system and Mental Disorders
10:30	S12-2	MARTA TORRENS (Barcelona, Spain, EU) - Mood Disorders and Opioid Use Disorder
11:00	S12-3	CARLOS RONCERO (Barcelona, Spain, EU) - Psychosis and Opioid system
11:30	S12-4	ICRO MAREMMANI (Pisa, Italy, EU) - How to manage Benzodiazepines Use Disorder during methadone treatment

Room and time	ABSTRACT No	
12:00		PARALLEL SYMPOSIA, SUNDAY MAY 27, 2018
Plenary Room	ABSTRACT No	13 - Hot topics in Heroin Use Disorder patients <i>Chair: Edward Jacek Gorzelańczyk (Bydgoszcz, Poland, EU)</i>
12:00	S13-1	AYMAN MOHSEN FAREED (Dahlonga, GA, USA) - The opioid overdose epidemic in the United States and the utilization of intranasal naloxone to reverse it
12:30	S13-2	EDWARD JACEK GORZELAŃCZYK (Bydgoszcz, Poland, EU) - Addiction and dual diagnosis in perspective o cortico-subcortical loop function
13:00	S13-3	HENRY LOTHANE (New York, NY, USA) - Addiction and humanistic treatment goals
13:30	S13-4	JOLANTA B. ZAWILSKA (Lodz, Poland, EU) - Novel psychoactive substances – new players in the old drama
Room A		14 - <i>in collaboration with International Society of Addiction Medicine (ISAM)</i> <i>Chair: Author (City, Country)</i>
12:00	S14-1	AUTHOR (City, Country) - Title
12:30	S14-2	AUTHOR (City, Country) - Title
13:00	S14-3	AUTHOR (City, Country) - Title
13:30	S14-4	AUTHOR (City, Country) - Title
Room B		15 - Title <i>Chair: Marc Auriacombe (Bordeaux, France, EU)</i>
12:00	S15-1	MARC AURIACOMBE (Bordeaux, France, EU) - Tbc
12:30	S15-2	AMINE BENYAMINA (Villejuif, France, EU) - Tbc
13:00	S15-3	JEAN-PIERRE DAULOUEDE (Bayonne, France, EU) - Tbc
13:30	S15-4	DIDIER TOUZEAU (Bagneux, France, EU) - Tbc
14:00	PL1c	ICRO MAREMMANI (Pisa, Italy, EU) - Conference Closing and Arrivederci aLisbon, Portugal, May 26-28, 2020

POSTER SESSION

ABSTRACT No	
P-01	SONILA BITRI TIVARI (Tirana, Albania) - Are we missing substance use disorders diagnosis in the emergency department ?
P-02	SONILA BITRI TIVARI (Tirana, Albania) - Alcohol use disorder and heroin addiction. What are the challenges?
P-03	MANUELE GLAUCO CARBONE (Pisa, Italy, EU) - The SCL90-based psychopathological structure may be applied in substance use disorder patients irrespectively of the involved drug also in heroin, alcohol and cocaine mono-drug users
P-04	FILIPPO DELLA ROCCA (Pisa, Italy, EU) - Further evidence of a psychopathology specific to Heroin Use Disorder. Relationships between psychopathological dimensions and addictive behaviours
P-05	MAURICE DEMATTEIS (Grenoble, France, EU) - Prevalence of opioid misuse in chronic opioid analgesic therapy for non-cancer pain is high in France
P-06	FELICIA HEIDEBRECHT (London, UK) - Practitioners' experiences of working with dual users of heroin and crack cocaine. A thematic analysis
P-07	FELICIA HEIDEBRECHT (London, UK) - Differences in treatment outcomes by frequency and drug preference for dual users of heroin and crack in opiate substitution therapy - A pilot study
P-08	MARION JOUHANNEAU (Villeneuve les Maguelone, France, EU) - Inventory of opiates addiction treatment (OAT) in prisons in France in 2017
P-09	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Excess suicide mortality in Heroin Use Disorder patients seeking Opioid Agonist Treatment in Slovenia and risk factors for suicide
P-10	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Capgras syndrome in a heroin addict. A case study
P-11	SORAYA MAYET (Hull, England, UK) - Effectiveness of opioid overdose and take-home naloxone training for staff
P-12	FADI MEROUEH (Villeneuve les Maguelone, France, EU) - The use of suboxone (buprenorphine and naloxone) in prison
P-13	HEATHER A. OLSEN (Denver, CO, USA) - Comparing prescription opioid use among heroin users using the RADARS® System EUROPAD program
P-14	PASQUALINA ROCCO (Marca Trevigiana, Italy, EU) - Attention Deficit Hyperactivity Disorder in Heroin Use Disorder patients
P-15	ANAT SASON (Tel Aviv, Israel) - Nutrition intervention among methadone maintenance treatment (MMT) patients and food addiction

Faculty

Adrian O. ABAGIU	National Institute for Infectious Diseases Prof Dr. Matei Bals (NIIDMB), Bucarest, Romania, EU - [E-Mail: adyaba@gmail.com]
Michael AMNON	Haifa University, Haifa, Israel - [E-Mail: haderech@netvision.net.il]
Mari AMOS	UN Subcommittee on Prevention of Torture, Tallin, Estonia, EU - [E-Mail: mari.amos@gmx.com]
Marc AURIACOMBE	Centre Hospitalier Charles Perrens - Pôle Addictologie - Bordeaux, France, EU - [E-Mail: marc.auriacombe@u-bordeaux.fr]
Iacopo BELCARI	Vincent P. Dole Dual Diagnosis Unit, Department of Specialty Medicine, Psychiatric Unit, Santa Chiara University Hospital, University of Pisa, Italy, EU - [E-Mail: iacopo.belcari@gmail.com]
Alexander BELCHEV	Turning Point South London, London, UK - [E-Mail: albelchev@gmail.com]
Amine BENYAMINA	Unité d'addictologie de l'hôpital Paul Brousse, Villejuif, France, EU - [E-Mail: abenyamina13@gmail.com]
Sonila BITRI TIVARI	Department of Clinical Toxicology and Addiction, American Hospital, Tirana, Albania - [E-Mail: sonila_bitri@yahoo.com]
Hagit BONNY-NOACH	Ariel University, Ariel, Israel - [E-Mail: hagitbo@gmail.com]
Manuele Glauco CARBONE	School of Psychiatry, University of Pisa, Italy, EU - [E-Mail: manuelglauco carbone@gmail.com]
Thomas CLAUSEN	Norwegian Centre for Addiction Research (SERAF), University of Oslo - [E-Mail: thomas.clausen@medisin.uio.no]
Olav DALGARD	Akershus University, Oslo, Norway - [E-Mail: ece.kucuksayrac@gilead.com]
Jean-Pierre DAULOUEDE	Centre Hospitalier de la Côte Basque, Bayonne, France, EU - [E-Mail: jeanpierredaulouede@gmail.com]
Paul DELANEY	coAim Sky Business Centre, Dublin, Ireland - [E-Mail: pdelaney3@gmail.com]
Mira DELIC	Center for Treatment of Drug Addiction, University Psychiatric Hospital Ljubljana - [E-Mail: mirjanadelic@yahoo.com]
Filippo DELLA ROCCA	V.P. Dole Research Team, Institute of Behavioural Sciences, Pisa, Italy, EU - [E-Mail: filippo.dellarocca@yahoo.it]
Maurice DEMATTEIS	CHU Grenoble-Alpes, Grenoble, France; INSERM UMR 987, Boulogne Billancourt, France; H6pital Cochin, Paris, France - [E-Mail: MDematties@chu-grenoble.fr]
Maurice DEMATTEIS	Department of Addiction Medicine, Grenoble-Alpes University Hospital, Grenoble, France, EU - [E-Mail: Dematteis Maurice <MDematteis@chu-grenoble.fr>]
Mojca Zvezdana DERNOVSEK	Educational Institute Mountain, Ljubljana, Slovenia, EU - [E-Mail: mojca_dernovsek@t-2.net]
Alice DESCHENAU	GH Paul Guiraud, Villejuif, France, EU - [E-Mail: alice.deschenau@gh-paulguiraud.fr]
Suzan Ben EZRA	Department of Treatment and Rehabilitation, Israel Anti-Drug Authority, Jerusalem, Israel - [E-Mail: suzanbe@antidrugs.gov.il]
Ayman Mohsen FAREED	Mount Sinai Wellness Center, Dahlenega, GA, USA - [E-Mail: ayman.fareed@mtsinaiwellness.com]
Loretta FINNEGAN	The College on Problems of Drug Dependence, Inc., Philadelphia, PA and Finnegan Consulting, Avalon, NJ, USA - [E-Mail: finnegan337@gmail.com]
Francina FONSECA	Institut de Neuropsiquiatria i Addiccions, Hospital del Mar, Barcelona, Spain, EU - [E-Mail: mffonseca@parcdesalutmar.cat]
Edward Jacek GORZELAŃCZYK	Department of Theoretical Basis of Bio-Medical Sciences and Medical Informatics, Nicolaus Copernicus University Collegium Medicum, Bydgoszcz, Poland, EU - [E-Mail: medsystem@medsystem.com.pl]
Aaron GREENBLATT	University of Maryland School of Medicine, Baltimore, MD, USA - [E-Mail: agreenbl@som.umaryland.edu]

Adam HAMED	Laboratory of Spatial Memory, Department of Cellular and Molecular Biology, Nencki Institute of Experimental Biology, Polish Academy of Sciences Warsaw, Poland - [E-Mail: a.hamed@nencki.gov.pl]
Martin HARALDSEN	Larvik Municipality - [E-Mail: martinharaldsen@outlook.com]
Dagmar HEDRICH	EMCDDA, Lisbon, Portugal - [E-Mail: Dagmar.Hedrich@emcdda.europa.eu]
Felicia HEIDEBRECHT	London South Bank University, London, UK - [E-Mail: felicias.research@gmx.de]
Felicia HEIDEBRECHT	London South Bank University, London, UK - [E-Mail: felicias.research@gmx.de]
Shirley HERTZ-KEISAR	Psychiatry Resident, Ness-Ziona – Be'er Yaacov Mental Health Medical Center, Ness Ziona, Israel - [E-Mail: shirleykeisar@hotmail.com]
Liljana IGNJATOVA	Centre for Prevention and Treatment of Drug Abuse and Addiction, Psychiatric Hospital Skopje, Skopje, Macedonia - [E-Mail: liljana.kiteva.ignjatov@medf.ukim.edu.mk]
Marion JOUHANNEAU	Unité Sanitaire - Maison d'Arrêt de Villeneuve les Maguelone, Villeneuve les Maguelone, France, EU - [E-Mail: f-meroueh@chu-montpellier.fr]
Alexander KANTCHELOV	The Kantchelov Clinic, Sofia, Bulgaria, EU - [E-Mail: al.kantchelov@gmail.com]
Karolina KARWOWSKA	Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland, EU - [E-Mail: karolina.m.karwowska@gmail.com]
Andrej KASTELIC	Center for Treatment of Drug Addiction, University Psychiatric Hospital Ljubljana & South Eastern European and Adriatic Addiction Treatment Network, Radomlje Homec, Slovenia, EU - [E-Mail: andrej.kastelic@guest.arnes.si]
Peter KASTNER	Ombudsman Institute Austria, Vienna, Austria - [E-Mail: peter.kastner@volksanwaltschaft.gv.at]
Riaz KHAN	- [E-Mail:
Michał KIEŁBIŃSKI	Institute of Applied Psychology, Jagiellonian University, Krakow, Poland, EU - [E-Mail: michal.kielbinski@uj.edu.pl]
Christos KOIUMSTIDITIS	- [E-Mail:
Arturo G. LERNER	Lev-Hasharon Mental Health Medical Center, Pardessya, Israel & Sackler School Of Medicine, Tel Aviv University, Ramat Aviv, Israel - [E-Mail: artura@lev-hasharon.co.il]
Henry LOTHANE	Icahn School of Medicine at Mount Sinai, New York, NY, USA - [E-Mail: medsystem@medsystem.com.pl]
Barbara LOVRECIC	National Institute of Public Health, Ljubljana, Slovenia, EU - [E-Mail: barbara.lovrecic@nijz.si]
Mercedes LOVRECIC	National Institute of Public Health, Ljubljana, Slovenia, EU - [E-Mail: mercedes.lovrecic@nijz.si]
Angelo G.I. MAREMMANI	Department of Psychiatry, North-Western Tuscany Region Local Health Unit, Versilian Zone, Viareggio, Italy, EU - [E-Mail: angelogimaremmanni@gmail.com]
Icro MAREMMANI	V.P. Dole Dual Disorder Unit, Santa Chiara University Hospital, University of Pisa, Italy, EU - [E-Mail: icro.maremmanni@med.unipi.it]
Rocio MARTIN-SANTOS	University of Barcelona, Spain - [E-Mail: rmsantos@clinic.ub.es]
Soraya MAYET	Humber NHS Foundation Trust, Hull, England, UK - [E-Mail: smayet@nhs.net]
Haim MELL	Yezreel Valley College, Afula, Israel - [E-Mail: mellhaim@012.net.il]
Fadi MEROUEH	Unité Sanitaire - Maison d'Arrêt de Villeneuve les Maguelone, Villeneuve les Maguelone, France, EU - [E-Mail: f-meroueh@chu-montpellier.fr]
Bodil MONWELL	Psychiatric clinic, County Hospital Ryhov/ Jönköping University, Sweden - [E-Mail: bodil.monwell@rjl.se]
Heather A. OLSEN	Rocky Mountain Poison & Drug Center, Denver Health, Denver, CO, USA - [E-Mail: karin.mcbride@rmpdc.org]
Yngvild OLSEN	Johns Hopkins University School of Medicine; Maryland State Department of Health, Baltimore, MD, USA - [E-Mail: Yngvild.olsen1@maryland.gov]
Matteo PACINI	G. De Lisi Institute of Behavioural Sciences, Pisa, Italy - [E-Mail: paciland@virgilio.it]

Mark PARRINO	American Association for the Treatment of Opioid dependence - AATOD, New York, NY, USA - [E-Mail: Mark.Parrino@aatod.org]
Einat PELES	Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse, Treatment and Research & Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel - [E-Mail: einatp@tlvmc.gov.il]
Einat PELES	Adelson clinic for Drug Abuse Treatment & Research, Tel Aviv Sourasky Medical Center & Sackler Faculty of Medicine, Tel Aviv University - [E-Mail: einatp@tlvmc.gov.il]
João G. PEREIRA	Romão de Sousa Foundation, Lisbon, Portugal, EU - [E-Mail: joao_pgpereira@hotmail.co.uk]
Marc REISINGER	EUROPAD & WFTOD, Brussels, Belgium, EU - [E-Mail: m.reisinger@proximus.be]
Pasqualina ROCCO	Servizio Dipendenze (Sero) U.L.S.S. n.2 Marca Trevigiana, Italy, EU - [E-Mail: pasqualina.rocco@aulss2.veneto.it]
Carlos RONCERO	Psychiatric Service, University of Salamanca Health Care Complex, Salamanca, Spain, EU - [E-Mail: croncero@saludcastillayleon.es]
Paola ROSCA	Department for the Treatment of Substance Abuse, Ministry of Health, Jerusalem, Israel - [E-Mail: paola.roska@MOH.GOV.IL]
Luca ROVAI	Department of Psychiatry, Northern-West Tuscany Region Local Health Unit, Apuan Zone, Massa, Italy, EU - [E-Mail: lucarovai@yahoo.com]
Anat SASON	Adelson clinic for Drug Abuse Treatment & Research, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel - [E-Mail: anatsas@tlvmc.gov.il]
Nusa SEGEC	University of Ljubljana, Faculty of Medicine, Department of Psychiatry, Ljubljana, Slovenia, EU - [E-Mail: nusa.segrec@psih-klinika.si]
Omri SINAI	Lev Hasharon Medical Center, affiliated to Tel Aviv University, Tel Aviv, Israel - [E-Mail: omrisinai@yahoo.com, ofirliv@gmail.com]
Wojciech SOLECKI	Institute of Applied Psychology, Jagiellonian University, Krakow, Poland, EU - [E-Mail: wojciech.solecki@uj.edu.pl]
Nestor SZERMAN	Department of Psychiatry, Hospital General Universitario Gregorio Marañón, Madrid, Spain, EU - [E-Mail: nszermanb@gmail.com]
Ilan TAL	Tal ambulatory Mental Health Center, Tel Aviv, Israel - [E-Mail: drtal@drtal.co.il]
Rok TAVCAR	University Psychiatric Hospital Ljubljana - [E-Mail: rok.tavcar@psih-klinika.si]
Marta TORRENS	IMIM Hospital del Mar Medical Research Institute, Department Neurosciences Research Programme, University of Barcelona, Barcelona, Spain, EU - [E-Mail: mtorrens@parcdesalutmar.cat]
Didier TOUZEAU	Clinique Liberté, Bagneux, France, EU - [E-Mail: didier.touzeau@gmail.com]
Albrecht ULMER	General Practitioner, Stuttgart, Germany, EU - [E-Mail: albrecht.ulmer@gmx.de]
Eric WEINTRAUB	University of Maryland School of Medicine, Baltimore, MD, USA - [E-Mail: eweintra@som.umaryland.edu]
Gabrielle Katrine WELLE-STRAND	SERAF - Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway - [E-Mail: Gabrielle.Katrine.Welle-Strand@helsedir.no]
Christopher WELSH	University of Maryland School of Medicine, Baltimore, MD, USA - [E-Mail: cwelsh@som.umaryland.edu]
Jamie WILLIAMS	Healing Therapy Services, Providence, Rhode Island, USA - [E-Mail: jfwww1@juno.com]
Jolanta B. ZAWILSKA	Department of Pharmacodynamics Medical University of Lodz, Poland, EU - [E-Mail: medsystem@medsystem.com.pl]

[Redacted content]



EUROPAD2018Krakow

European Opiate Addiction Treatment Association | Congress



European Union of Medical Specialists

EACCME - European Accreditation Council for Continuing Medical Education

Institution of the UEMS

Rue de l'Industrie 24, B-1040, Brussels

T: +32 2 649 5164 | F: +32 2 640 37 30 | E: accreditation@uems.eu

The 13th EUROPAD Conference was granted xx European CME credits (ECMEC)
by the European Accreditation Council for Continuing Medical Education (EACCME)

Platinum sponsors



MOLTENI
FARMACEUTICI



MSD